Atlas Trials

Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT01278615 · TERMINATED

Trial details

NCT number
NCT01278615
Sponsor
National Cancer Institute (NCI)
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Adult Diffuse Large Cell Lymphoma
Start date
2010-12-01
Primary completion
2014-02-01
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.